Miranda Schmalfuhs

Tom McCourt, CEO of Ironwood Pharmaceuticals, talks about his 30-plus years in the gastrointestinal space, including his experiences bringing top GI medicines Prilosec, Nexium, Entocort, Zelnorm, and Linzess to market.

Dr. Michael Henderson, chief business officer of BridgeBio Pharma, and one of Pharm Exec’s 2021 Emerging Pharma Leaders, discusses how his company goes beyond the traditional “hand off” approach between academia and industry, and looks to partner with institutions early on to fill important voids in drug development.

Looking Back at 2007–2010.

Dr. Edith Perez, Chief Medical Officer of Bolt Biotherapeutics, discusses how she approaches drug development in oncology, and what she contributes outside of work to help raise awareness for cancer.

Audrey Greenberg, co-founder and executive managing director of the Center for Breakthrough Medicines and Discovery Labs, discusses how cell and gene therapy has turned Philadelphia into Cellicon Valley, and how her organization is playing a role in that growth even beyond the city’s borders.

Our editorial team presents the winners of our annual Emerging Pharma Leaders and their up-and-coming perspectives on a range of industry topics.

Early career ‘assist’ ignites calling in data and healthcare disruption.

Excelling in specialty launch while paying it forward.

Looking Back at 1994–1996.

Looking back at 1986-1989.

Addressing the need for fast-acting therapy in treatment-resistant depression.

A look at the ongoing barriers and opportunities in building connections between HCPs, patients, and pharma through social media.